Search results for "Recombinant Proteins"

showing 10 items of 697 documents

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct

Leptin and leptin receptor expression in asthma.

2009

Background The adipokine leptin is a potential new mediator for bronchial epithelial homeostasis. Asthma is a chronic inflammatory disease characterized by airway remodeling that might affect disease chronicity and severity. TGF-β is a tissue growth factor the dysregulation of which is associated with airway remodeling. Objective We sought to determine whether a bronchial epithelial dysfunction of the leptin/leptin receptor pathway contributes to asthma pathogenesis and severity. Methods We investigated in vitro the presence of leptin/leptin receptor on human bronchial epithelial cells. Then we studied the effect of TGF-β and fluticasone propionate on leptin receptor expression. Finally, th…

AdultLeptinMalemedicine.medical_specialtyPyridinesMorpholinesImmunologyAdipokineBronchiRespiratory MucosaSettore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - FisiologiaCell LinePathogenesisTransforming Growth Factor beta1Leptin leptin receptor severe asthma epithelium TGF-b remodelingInternal medicineImmunology and AllergyMedicineHumansEnzyme InhibitorsReceptorCell ProliferationLeptin receptorbusiness.industryTumor Necrosis Factor-alphaLeptindigestive oral and skin physiologyImidazolesMiddle AgedEpitheliumAsthmaRecombinant Proteinsrespiratory tract diseasesAndrostadienesmedicine.anatomical_structureEndocrinologyChromonesImmunologyFluticasoneReceptors LeptinFemalebusinesshormones hormone substitutes and hormone antagonistsEx vivoTransforming growth factorThe Journal of allergy and clinical immunology
researchProduct

Expression of properdin in human monocytes

1994

Properdin is the only known positive regulator of the alternative pathway of complement activation. Northern blot analysis of cell lines derived from fibroblasts, B-cells, hepatoma cells, and cells of the monocyte-macrophage lineage revealed properdin expression only in the myelomonocytic cell line HL-60, in the monoblastic cell line U-937 and in the monocytic line Mono Mac 6. Culture of Mono Mac 6 cells for 24 h with phorbol 12-myristate 13-acetate, bacterial lipopolysaccharide and the cytokines interleukin-1 beta and tumour necrosis factor-alpha enhanced mRNA abundance, with the strongest effect (tenfold) being observed with the lipopolysaccharide. In contrast, recombinant interferon-gamm…

AdultLipopolysaccharidesLipopolysaccharidemedicine.medical_treatmentMolecular Sequence DataEnzyme-Linked Immunosorbent AssayBiologyurologic and male genital diseasesBiochemistryMonocytesCell LineInterferon-gammachemistry.chemical_compoundTumor Cells CulturedmedicineHumansRNA MessengerNorthern blotBase SequenceProperdinTumor Necrosis Factor-alphaMacrophagesMonocyteBlotting NorthernMolecular biologyRecombinant ProteinsComplement systemCytokinemedicine.anatomical_structurechemistryCell cultureImmunologyAlternative complement pathwayCytokinesTetradecanoylphorbol AcetateProperdinInterleukin-1European Journal of Biochemistry
researchProduct

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin…

2010

EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients.Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV) analyses were performed us…

AdultLiver CirrhosisMaleBiopsyFibrotestInterferon-alphaAlanine TransaminaseHepatitis C ChronicInterferon alpha-2Middle AgedPrognosisRecombinant ProteinsPolyethylene GlycolsFatty LiverRibavirinHumansDrug Therapy CombinationFemaleProspective Studies
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

2007

Aims To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naı¨ve’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results Forty-eightpatientswereincluded(M/F28/20;meanage50.0 12.6years; 62.5% genotype-1). Body mass index was 26.4 4.0 kg/m2 , and visceral obesity was present in 24…

AdultLiver CirrhosisMaleInterferon-alphahcv steatosisHepatitis C ChronicInterferon alpha-2Intra-Abdominal FatMiddle AgedAntiviral AgentsRecombinant ProteinsFatty LiverRibavirinAdipocytesHumansFemaleObesityInsulin ResistanceAlimentary pharmacologytherapeutics
researchProduct

Growth hormone replacement in adults:Real-world data from two large studies in US and Europe

2020

Objective: This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0–12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905). Design: In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of the treating physician and according to routine practice. We present data on baseline characteristics, growth hormone dose, safety data and change from baseline in waist circumferenc…

AdultMale0301 basic medicineIGF-I SDSPediatricsmedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and MetabolismANSWER Program030209 endocrinology & metabolismEffectivenessGrowth hormoneNordiNet® International Outcome Study (IOS)Body compositionHypopituitarismBody Mass IndexGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyElectric ImpedancemedicineHumansGrowth hormone replacementAgedAdult patientsHuman Growth Hormonebusiness.industryMiddle Agedmedicine.diseaseRecombinant ProteinsUnited StatesReal-world dataEuropeClinical Practice030104 developmental biologyGrowth hormone deficiency in adultsBaseline characteristicsBody CompositionFemaleWaist CircumferenceSafetybusinessReal world dataBody mass index
researchProduct

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in pati…

1993

After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte - colony stimulating factor (G- CSF) 5 μg/Kg/day in order to prevent severe neutropenia and its related morbidity. The incidence of neutropenia (absolute neutrophil count <1, 000/mm3) was significantly reduced in patients receiving G-CSF than in controls (18% versus 42%; P <0.05). The duration of neutropenia was also shortened by the administration of G-CSF (4.8 versus 8.2 days; P <0.05). Therapy with G-CSF has also a positive impact on the dose-intensity of employed regimens. Patients treated with G-CSF showed…

AdultMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeutropeniaTime FactorsFeverInjections Subcutaneousmedicine.medical_treatment030106 microbiologyAntineoplastic AgentsNeutropeniaGranulocytePlaceboGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Prospective StudiesNeoplasm MetastasisAgedPharmacologyChemotherapybusiness.industryIncidenceIncidence (epidemiology)CarcinomaMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryInfectious DiseasesGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncology030220 oncology & carcinogenesisAbsolute neutrophil countFemalebusinessmedicine.drug
researchProduct

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before an…

2020

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Disorders (MetabERN), Monza, Italy; 2TIGET Institute, IRCCS San Raffaele Hospital, Milan, Italy; 3Division of Rare Diseases, Reference Centre for Hereditary Metabolic Disorders (MetabERN), University Hospital Vall d&amp;rsquo;Hebron, Autonomous University of Barcelona, Barcelona, Spain; 4Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany; 5Dep…

AdultMale0301 basic medicinemedicine.medical_specialtyestimated glomerular filtration rateAdolescentPharmaceutical ScienceRenal functionLeft ventricular hypertrophyFabry Outcome SurveyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineHumansEnzyme Replacement TherapyEstimated glomerular filtration rateChildAgalsidase alfaOriginal ResearchRetrospective StudiesPharmacologyagalsidase alfaFabry diseaseProteinuriaDrug Design Development and Therapybusiness.industryLeft ventricular hypertrophyEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsleft ventricular hypertrophyIsoenzymesTreatment Outcome030104 developmental biologyMale patientalpha-Galactosidase030220 oncology & carcinogenesisEnzyme replacement therapyCohortmedicine.symptombusinessAgalsidase alfa
researchProduct